JAK2 and cancer: EGFR/JAK2/STAT5b is also included in PD-L1-dependent cancer cell proliferation, and targeting this signaling pathway in NSCLC could be interesting due to EGFR overexpression, which is highly associated with many NSCLC cells, including A549 and H460 [53].